Pliant Therapeutics grants 60,000 stock options

PLIANT THERAPEUTICS, INC. director Robert Iannone received a grant of 60,000 stock options on July 9, 2026.

Rhea-AI Filing Summary

PLIANT THERAPEUTICS, INC. director Robert Iannone received a grant of 60,000 stock options on July 9, 2026. The options have an exercise price of $1.13 per share and are exercisable for common stock until July 9, 2036. According to the vesting terms, 1/36th of the options vest in substantially equal monthly installments on each monthly anniversary of July 9, 2026, conditioned on Iannone’s continuous service to the company.

Insider Trade Summary

Grant/Award: 60,000 shares

Grant/Award 1 txn

Insider Iannone Robert

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	60,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 60,000 contracts (Direct)

Footnotes (1)

1. F1. 1/36th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of July 9, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Key Figures

Option Shares Granted: 60,000 shares Exercise Price: $1.13 per share Expiration Date: July 9, 2036 +3 more

6 metrics

Option Shares Granted 60,000 shares Stock option grant on July 9, 2026 to director Robert Iannone

Exercise Price $1.13 per share Conversion or exercise price of the granted stock options

Expiration Date July 9, 2036 Expiration of the 60,000-share stock option grant

Underlying Shares 60,000 shares Common stock underlying the reported stock option

Post-Grant Derivative Holdings 60,000 options Total derivative securities following the reported grant

Vesting Schedule 1/36th monthly Monthly vesting on each anniversary of July 9, 2026, over 36 installments

Key Terms

Stock Option (Right to Buy), exercise price, vesting, continuous service

4 terms

Stock Option (Right to Buy) financial

"security_title is reported as Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price is disclosed as 1.1300 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"1/36th of the shares subject to such option vest and become exercisable"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continuous service financial

"subject to the Reporting Person's continuous service to the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Robert Iannone report in his latest Form 4 for PLRX?

Robert Iannone reported a grant of 60,000 stock options for PLIANT THERAPEUTICS, INC. The options are exercisable for common stock at an exercise price of $1.13 per share and expire on July 9, 2036.

What is the exercise price of Robert Iannone’s new stock options in PLRX?

The granted stock options carry an exercise price of $1.13 per share. These options allow purchase of PLIANT THERAPEUTICS, INC. common stock at that price through their July 9, 2036 expiration, subject to the vesting schedule.

How many PLRX shares are covered by Robert Iannone’s new option grant?

The new option award covers 60,000 shares of PLIANT THERAPEUTICS, INC. common stock. All 60,000 underlying shares are tied to a single stock option grant that vests over time based on continued service.

When do Robert Iannone’s PLRX stock options start vesting and how?

The options begin vesting on July 9, 2026. 1/36th of the 60,000 options vest in substantially equal monthly installments on each monthly anniversary, conditioned on his continuous service to PLIANT THERAPEUTICS, INC.

When do Robert Iannone’s PLRX stock options expire?

The options expire on July 9, 2036. Until that date, vested portions of the 60,000-share stock option grant may be exercised at the fixed exercise price of $1.13 per share, subject to the award terms.

Is Robert Iannone’s PLRX Form 4 transaction a market purchase or a grant?

The reported transaction is a grant/award acquisition of stock options, not an open-market trade. It is coded as an "A" transaction, reflecting a compensation-related option award with no purchase price paid for the grant itself.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 04:32 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Iannone Robert

(Last) (First) (Middle)

C/O PLIANT THERAPEUTICS, INC.

331 OYSTER POINT BOULEVARD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PLIANT THERAPEUTICS, INC. [ PLRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.13	07/09/2026		A		60,000		(1)	07/09/2036	Common Stock	60,000	$0	60,000	D

Explanation of Responses:

1. 1/36th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of July 9, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

	/s/ Jennifer Woo, attorney-in-fact	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)